HilleVax, Inc.

Historical 13F Holders

Reported Value, Excluding Options

Total Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 43157M102 since 12/18/2024, largest first.

Filer	% of Class	Shares	Form	Filed
Under 5%, checked the "5 percent or less" box, or amended by a later filing (4)
EcoR1 Capital, LLC 13G/A	0%	0	13G/A	11/14/2025 Event 9/30/2025
EcoR1 Capital, LLC	0%	0
Oleg Nodelman	0%	0
EcoR1 Capital Fund Qualified, L.P.	0%	0
Frazier Life Sciences Public Fund, L.P. 13D/A	0%	0	13D/A	9/17/2025 Event 9/17/2025
Frazier Life Sciences Public Fund, L.P.	0%	0
FHMLSP, L.P.	0%	0
FHMLSP, L.L.C.	0%	0
Frazier Life Sciences Public Overage Fund, L.P.	0%	0
FHMLSP Overage, L.P.	0%	0
FHMLSP Overage, L.L.C.	0%	0
Frazier Life Sciences X, L.P.	0%	0
FHMLS X, L.P.	0%	0
FHMLS X, L.L.C.	0%	0
Frazier Life Sciences XI, L.P.	0%	0
FHMLS XI, L.P.	0%	0
FHMLS XI, L.L.C.	0%	0
James N. Topper	0%	0
Patrick J. Heron	0%	0
Albert Cha	0%	0
James Brush	0%	0
Daniel Estes	0%	0
Takeda Pharmaceutical Co Ltd 13D/A	0%	0	13D/A	9/19/2025 Event 9/17/2025
Takeda Pharmaceutical Company Limited	0%	0
Takeda Vaccines Inc.	0%	0
Tang Capital Management LLC 13D/A	0%	0	13D/A	9/19/2025 Event 9/17/2025
Tang Capital Management, LLC	0%	0
Kevin Tang	0%	0
Tang Capital Partners, LP	0%	0
Tang Capital Partners International, LP	0%	0
Tang Capital Partners III, Inc	0%	0
Tang Capital Partners IV, Inc	0%	0
Concentra Biosciences, LLC	0%	0

Period	Filings	Shares, Excl. Options	Value, Excl. Options	Options Value
2025 Q3	1	179 k	$0	$0
2025 Q2	78	41.6 M	$82.6 M	$0
2025 Q1	82	42.2 M	$61.5 M	$0
2024 Q4	77	42.8 M	$88.7 M	$0
2024 Q3	81	41.8 M	$73.5 M	$0
2024 Q2	99	45.6 M	$659 M	$0
2024 Q1	85	44.1 M	$733 M	$0
2023 Q4	73	42.8 M	$686 M	$0
2023 Q3	69	34.1 M	$459 M	$0
2023 Q2	55	25.4 M	$437 M	$0
2023 Q1	64	26.4 M	$436 M	$0
2022 Q4	57	26.6 M	$445 M	$0
2022 Q3	52	23.4 M	$400 M	$0
2022 Q2	58	23.2 M	$254 M	$0